Study offers clues to precision treatments for lukemia
Clues to precision treatments for a tough childhood leukemia
Researchers reveal genetic secrets of a high-risk pediatric leukemia called Ph-ALL, and find treatment potential in the drug ruxolitinib.
A promising anti-inflammatory drug tames the immune system
The drug ruxolitinib shows promise in targeting inflammatory reactions in the immune disorder hemophagocytic lymphohistiocytosis (HLH).
Parental influence extends to drug response
Researchers demonstrate how differences in inherited genetic makeup can cause problems during leukemia treatment.
Understanding how brain tumor treatment affects the brain
An unprecedented study finds that survivors of childhood brain tumors are at risk of memory and intelligence deficits. A key goal? Catch them early.
From Promise, Spring 2016